Phase II Trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy

被引：1
|
作者：
Wenham, R. [1 ]
LaPolla, J. [2 ]
Hui-Yi, L. [1 ]
Apte, S. [1 ]
Roberts, W. [1 ]
Lancaster, J. [1 ]
Bosquet, J. Gonzalez [1 ]
Theodore, S. [1 ]
Havrilesky, L. [3 ]
Alvarez-Secord, A. [3 ]
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[2] Womens Canc Associates, St Petersburg, FL USA
[3] Duke Univ, Med Ctr, Durham, NC USA
来源：
GYNECOLOGIC ONCOLOGY | 2011年 / 121卷 / 01期
关键词：
D O I：
10.1016/j.ygyno.2010.12.199
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
192
引用
收藏
页码：S83 / S84
页数：2
相关论文
共 50 条
  • [1] A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy
    Wenham, R.
    LaPolla, J.
    Lin, H.
    Apte, S.
    Roberts, W.
    Lancaster, J.
    Theodore, S.
    Fabri, D.
    Havrilesky, L.
    Alvarez-Secord, A.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S61 - S62
  • [2] A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy
    Wenham, Robert M.
    Lapolla, James
    Lin, Hui-Yi
    Apte, Sachin M.
    Lancaster, Johnathan M.
    Judson, Patricia L.
    Gonzalez-Bosquet, Jesus
    Herschberger, Amber
    Havrilesky, Laura J.
    Secord, Angeles Alvarez
    GYNECOLOGIC ONCOLOGY, 2013, 130 (01) : 19 - 24
  • [3] Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy
    Colombo, Nicoletta
    Gore, Martin
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 64 (02) : 129 - 138
  • [4] BEVACIZUMAB AND PLATINUM-BASED CHEMOTHERAPY IN RELAPSED OVARIAN CANCER TREATMENT
    Davidenko, I.
    Kazantseva, M.
    Porhanova, N.
    Potemin, S.
    Oganyan, M.
    Syrota, L.
    Shmatkova, V.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [5] Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
    Pfisterer, Jacobus
    Shannon, Catherine M.
    Baumann, Klaus
    Rau, Joern
    Harter, Philipp
    Joly, Florence
    Sehouli, Jalid
    Canzler, Ulrich
    Schmalfeldt, Barbara
    Dean, Andrew P.
    Hein, Alexander
    Zeimet, Alain G.
    Hanker, Lars C.
    Petit, Thierry
    Marme, Frederik
    El-Balat, Ahmed
    Glasspool, Rosalind
    de Gregorio, Nikolaus
    Mahner, Sven
    Meniawy, Tarek M.
    Park-Simon, Tjoung-Won
    Mouret-Reynier, Marie-Ange
    Costan, Cristina
    Meier, Werner
    Reinthaller, Alexander
    Goh, Jeffrey C.
    L'Haridon, Tifenn
    Hay, Sally Baron
    Kommoss, Stefan
    du Bois, Andreas
    Kurtz, Jean-Emmanuel
    LANCET ONCOLOGY, 2020, 21 (05): : 699 - 709
  • [6] Phase I trial of ribociclib (LEE-011) with platinum-based chemotherapy in recurrent platinum sensitive ovarian cancer
    Coffman, Lan
    Orellana, Taylor
    Normolle, Daniel
    Courtney-Brooks, Madeleine
    Boisen, Michelle
    Olawaiye, Alexander
    Berger, Jessica
    Lesnock, Jamie
    Sukumvanich, Paniti
    Taylor, Sarah
    McLean, Karen
    Uppal, Shitanshu
    Buckanovich, Ronald
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S69 - S69
  • [7] OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab
    Hardesty, Melissa M.
    Krivak, Thomas C.
    Wright, Gail S.
    Hamilton, Erika
    Fleming, Evelyn L.
    Belotte, Jimmy
    Keeton, Erika K.
    Wang, Ping
    Gupta, Divya
    Clements, Aine
    Gray, Heidi J.
    Konecny, Gottfried E.
    Moore, Richard G.
    Richardson, Debra L.
    GYNECOLOGIC ONCOLOGY, 2022, 166 (02) : 219 - 229
  • [8] Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment
    Lee, Jung-Min
    Annunziata, Christina M.
    Hays, John L.
    Cao, Liang
    Choyke, Peter
    Yu, Minshu
    An, Daniel
    Turkbey, Ismail Baris
    Minasian, Lori M.
    Steinberg, Seth M.
    Chen, Helen
    Wright, John
    Kohn, Elise C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 (01) : 88 - 94
  • [9] Effect of prior olaparib maintenance therapy for platinum sensitive recurrent ovarian cancer on response to subsequent platinum-based chemotherapy
    Nakazawa, Hiroshi
    Nagao, Shoji
    Narita, Moyu
    Shibutani, Takashi
    Jimi, Tomoatsu
    Yano, Hiroko
    Kitai, Miho
    Shiozaki, Takaya
    Yamaguchi, Satoshi
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2022, 48 (05) : 1248 - 1254
  • [10] A phase II trial of gefitinib in recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy
    Chua, D. T.
    Sham, J.
    Au, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345